EMERYVILLE, Calif., May 13, 2013 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), a leading renewable chemicals and fuels company, announced today the appointment of R. Neil Williams, Chief Financial Officer of Intuit, as a member of Amyris's Board of Directors and the Chair of the Audit Committee. " We are pleased with the addition of Neil to our Board. He brings extensive financial, corporate strategy and execution experience to help us build on our strategic direction and momentum," said John Melo, President & CEO of Amyris. " We are pleased Patrick Pichette , who served on our board for the last three years, has agreed to stay as a member of our strategic advisory board," Melo concluded. " I look forward to supporting Amyris's cutting edge technology development and growth-strategy execution. Amyris's synthetic biology platform, now operating at industrial scale in Brazil, offers considerable opportunities across a broad range of renewable chemical and fuel applications," said Neil Williams. R. Neil Williams has been Senior Vice President and Chief Financial Officer of Intuit, Inc. since January 2008. Mr. Williams has a thirty-year career in the financial services industry. At Intuit, he has been responsible for all financial aspects of the company, including corporate strategy and business development, investor relations, financial operations and real estate. Before joining Intuit, Williams was the Executive Vice President and Chief Financial Officer for Visa U.S.A., Inc. In that role, he led all financial functions for the company and its subsidiaries, including financial planning, business planning and financial monitoring. His previous banking experience includes senior financial positions at commercial banks in the Southern and Midwest regions of the United States. Williams, a certified public accountant, received his bachelor's degree in business administration from the University of Southern Mississippi. In addition to Mr. Williams, Amyris's Board of Directors is composed of its Chairman, Arthur Levinson, Chairman of Apple Inc. and Genentech, Inc.; Ralph Alexander, Managing Director at Riverstone Holdings, LLC; Philippe Boisseau, President, Supply-Marketing and New Energies divisions and a member of the Executive Committee of Total S.A.; Nam-Hai Chua, Professor and Head of the Laboratory of Plant Molecular Biology at Rockefeller University; John Doerr, Partner at Kleiner Perkins Caufield & Byers; Geoffrey Duyk, Partner at TPG Biotech; John Melo; Carole Piwnica, Director of Naxos UK; Fernando Reinach, Managing Partner of Pitanga Fund; and, HH Sheikh Abdullah bin Khalifa Al Thani of Qatar. About Amyris Amyris is an integrated renewable products company focused on providing sustainable alternatives to a broad range of petroleum-sourced products. Amyris uses its industrial synthetic biology platform to convert plant sugars into a variety of molecules -- flexible building blocks that can be used in a wide range of products. Amyris's initial portfolio of commercial products is based on Biofene®, Amyris's brand of renewable farnesene, a long-chain hydrocarbon. Amyris is commercializing these products both as No Compromise® renewable ingredients in cosmetics, flavors and fragrances, polymers, lubricants and consumer products, and also as No Compromise renewable diesel and jet fuel. Amyris Brasil Ltda., a subsidiary of Amyris, oversees the establishment and expansion of Amyris's production in Brazil. More information about Amyris is available at www.amyris.com. Forward-Looking Statements This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as potential product applications and growth) that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including those associated with any delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris's reliance on third parties to achieve its goals, and other risks detailed in the "Risk Factors" section of Amyris's Form 10-Q filed on May 9, 2013. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise. Amyris, the Amyris logo, Biofene and No Compromise are trademarks or registered trademarks of Amyris, Inc.
CONTACT: Amyris, Inc. Joel Velasco (510) 740-7481 firstname.lastname@example.org